Navigation Links
Study Identifies Large Concentration of Contract Research Assets in Kansas City Region
Date:6/21/2011

CHICAGO, June 21, 2011 /PRNewswire-USNewswire/ -- According to a new study released today at the annual meeting of the Drug Information Association in Chicago, the greater Kansas City region is home to a significant cluster of contract research organizations (CROs) and contract service providers (CSPs), with more than $1 billion in annual revenue.

Commissioned through an innovative partnership consisting of the Kansas Bioscience Authority, the Kansas Bio Organization, the Kansas City Area Life Sciences Institute and the Kansas City Area Development Council, the study also found that the Kansas City region is home to approximately 70 CROs and CSPs employing more than 9,000 people.

"Working with our regional partners, we commissioned this study because we knew there was a wealth of contract research and service activity in the region," said David Vranicar, interim president and CEO of the Kansas Bioscience Authority, "but it was surprising – even to those of us who know the space well – to learn that this is an industry that exceeds one billion dollars in revenue locally. Of equal significance is the diversity of the region's CRO and contract service provider offerings, spanning every stage of drug development required to identify and bring new drugs and devices to market."

Nearly every major global pharmaceutical company has utilized contract research services in the Kansas City region.

Increasing pressure on pharmaceutical and biotech companies to address unmet medical needs is driving demand for CROs and CSPs to deliver high-quality contract research. Outsourcing these activities gives drug developers increased flexibility to accommodate research and staffing constraints in their development pipelines. By leveraging the specific research experience provided by CROs and CSPs, outsourcing can significantly lower costs and shorten timelines.

"Research sponsors need to be confident that CROs and CSPs can deliver rigorous scientific results efficiently," said Peter Simon, founder of the Wellesley, Mass.-based Simon Management Group, who conducted the research. "The decision of a sponsor to utilize a particular CRO or contract service provider is often driven by referrals and personal recommendations, which offer an assurance of quality and efficiency. What is impressive about the Kansas City CRO and service provider community is that it can meet the large-scale needs of major pharmaceutical companies and provide the more personal, hands-on partnerships valued by many emerging biotech companies.  These are experienced companies with proven track records."

"The presence of so many experienced and reputable CROs and CSPs in the Kansas City region represents a significant benefit to biotech and pharmaceutical research sponsors," said Angela Kreps, president of Kansas Bioscience Organization. "A tightly-knit network of CROs and CSPs enables regional referrals that can save research sponsors time and money – both of which are top priorities in drug development. We believe these findings represent an opportunity to work together to grow our regional offerings and attract even more companies, employees, and investors. We see one billion in annual revenue as the start, not the end, of our efforts to develop this regional asset."

To learn more about Kansas City's regional contract research organizations and CSPs, contact one of the following partner organizations:



'/>"/>
SOURCE Kansas Bioscience Authority
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Tie-up with Government hospitals as ... to save newborns   Fortis La Femme, ... collaboration with Breast Milk Foundation (BMF), a non-profit organization within ... Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes that ... and should be available to babies deprived of mother,s milk.  ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):